enGene Holdings: Still A Buy After A Massive Surge

Core Insights - The article expresses optimism about enGene Holdings Inc. (ENGN) in the context of bladder cancer research and investment potential [1] Company Analysis - enGene Holdings Inc. is focused on developing therapies for bladder cancer, indicating a specialized niche within the biotech sector [1] - The author has a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, which adds credibility to the insights provided [1] Investment Thesis - The investment thesis for enGene Holdings Inc. is based on its market valuation relative to its potential in the bladder cancer treatment space, suggesting that the company may be undervalued [1]